Abstract | In tumour immunology, complement has traditionally been considered as an adjunctive component that enhances the cytolytic effects of antibody-based immunotherapies, such as rituximab. Remarkably, research in the past decade has uncovered novel molecular mechanisms linking imbalanced complement activation in the tumour microenvironment with inflammation and suppression of antitumour immune responses. These findings have prompted new interest in manipulating the complement system for cancer therapy. This Review summarizes our current understanding of complement-mediated effector functions in the tumour microenvironment, focusing on how complement activation can act as a negative or positive regulator of tumorigenesis. It also offers insight into clinical aspects, including the feasibility of using complement biomarkers for cancer diagnosis and the use of complement inhibitors during cancer treatment.
An enormous body of data produced by converging disciplines has provided unprecedented insight into the intricate and dynamic relationship that exists between developing tumours and the host immune system [1] [2] [3] . It is widely accepted that neoplastic transformation is a multifactorial process that the immune system can detect through genetic and epigenetic changes that alter the antigenic signatures of tumour cells. Control of tumour growth relies on both innate and adaptive mechanisms of immunosurveillance and is subject to the selective pressure exerted by distinct immuno regulatory pathways in the tumour microenvironment [4] [5] [6] [7] . In this regard, cancer treatment has been revolutionized by new immuno modulatory approaches that elicit durable clinical responses in cancer patients by restoring anti tumour immunity and potentiating standard therapeutic regimens, such as tumour radiotherapy 5, 8 . Elements of the innate immune response are inte gral components of antitumour effector mechanisms 3, 9 . In many ways, tumour cells are perceived by the innate immune system as noxious, 'nonself ' matter that must be disposed of 10 . Therefore, potent antitumour cytotoxic responses are elicited by innate immune cells, followed by elimination of opsonized tumour cells through the concerted action of tumourdirected antibodies and complement 9, 11, 12 . Complement is a phylogenetically conserved branch of the innate immune response that has traditionally been perceived as a network of proteins that rapidly respond to microbial intruders, triggering the release of inflammatory mediators, phagocytic responses and cell lysis 13 
. Growing evidence has indicated, however, that this versatile innate immune effector system mediates key homeostatic functions in processes ranging from early vertebrate development and tissue morphogenesis to tissue regeneration, cen tral nervous system synaptic pruning, host-microbiota symbiosis and adaptive immune regulation [14] [15] [16] [17] . In the context of cancer immunotherapy, complement can be readily triggered into action by damageassociated molecular patterns (DAMPs) exposed on the surface of tumour cells 3, 6 . Although the role of complement as an effector mechanism that potentiates antibody dependent tumour cytolysis has been long appreciated, clinical challenges, such as the upregulation of a wide spectrum of complement regulatory proteins, remain to be addressed 12, 18, 19 . Clearly, the role of complement as an effector of tumour cytotoxic responses remains relevant to antibody mediated immunotherapy, guiding new thera peutic options. Intriguingly, however, accumu lating evidence from studies published in the past decade has pointed to a fascinating paradigm shift: the real ization that complement activation within the tumour microenvironment can serve a tumourpromoting role by perpetuating local T cell immuno suppression and chronic inflammation that promotes tumour immune escape, outgrowth and metastasis [20] [21] [22] [23] . Diverse complement derived effectors and downstream sig nalling partners have been implicated in processes ranging from tumour cell anchorage and proliferation to tumourassociated angiogenesis, matrix remodel ling, migration, tissue invasiveness and metastasis 6, 19 .
With new insights being gained from a variety of tumour models, it is becoming clear that the contribution of com plement to cancer pathophysiology is far more complex than originally thought and appears to be largely contex tual, depending on several factors, such as the cellular origin of the tumour in question, its inherent capacity to produce autologous complement proteins, the nature of the tumour microenvironment and the magnitude of complement activation.
In this Review, we discuss current and emerging aspects of complement's contribution to cancer elim ination and progression and suggest therapeutic tar gets with clinical potential. We also place emphasis on clinical challenges faced in translating these findings to efficacious tumour cytotoxic modalities or combination immunotherapies and interrogate the feasibility of using complementbased biomarkers for cancer diagnosis, tumour staging and prognosis.
Complementing cancer immunotherapy
There is a growing appreciation that durable clinical responses in patients with cancer are more likely to be achieved when targeted therapies that ablate key onco genic signalling pathways are combined with approaches that effectively reverse tumourinstigated immuno suppression and augment antitumour immunity -an example has been the success of immune checkpoint blockade 5, 8 . Among the currently explored targeted therapies, monoclonal antibody (mAb)-based cancer immunotherapy has gained considerable traction as a
Box 1 | An overview of the complement system
The complement system comprises an extensive network of fluid-phase and membrane-bound glycoproteins, cofactors, receptors and regulatory proteins that engage in innate immune recognition, adaptive cell stimulation and pro-inflammatory effector responses 126 . Being a crucial mediator of tissue immunosurveillance, complement responds rapidly to molecular stress signals through a cascade of sequential proteolytic reactions initiated by the binding of pattern recognition molecules (for example, C1q, mannose-binding lectin (MBL), MBL-associated serine proteases (MASPs), ficolins and properdin (also known as Factor P)) to distinct structures on damaged cells, biomaterial surfaces or microbial intruders 17 . Whereas three 'canonical' pathways of activation have been described to date (that is, the classical, alternative and lectin pathways), mounting evidence indicates that complement can be activated via multiple routes, depending on the initiating triggers and the distinct microenvironment or pathophysiological context 126 . The classical pathway is initiated by binding to circulating or surface-bound immune complexes, while the lectin and alternative pathways are triggered by pathogenassociated molecular patters (PAMPs) or aberrant carbohydrate structures on damaged or necrotic cells. All activation pathways converge at the cleavage of C3, an abundant plasma protein that undergoes elaborate conformational changes upon activation, thereby exposing multiple sites of interaction with diverse immune effectors 127 . Notably, the spontaneous low-level hydrolysis of C3 keeps the alternative pathway in 'standby' mode to allow for rapid amplification upon microbial challenge 128 . Complement activation culminates in the assembly of short-lived multiprotein complexes with enzymatic activity termed 'convertases'. These enzymes are responsible for the proteolytic activation of the central components C3 and C5 and the release of their respective bioactive fragments, C3a and C3b, and C5a and C5b. The rapid amplification of C3b deposition via the alternative pathway is a process known to underlie several clinical disorders associated with genetic or acquired complement dysregulation (for example, C3 glomerulopathy) 17, 129 . Cleavage of C5 leads to the release of the potent inflammatory mediator C5a and initiates a sequence of protein-protein interactions that induces assembly of the membrane attack complex (MAC, C5b-C9), a multiprotein 'pore' with cell activating and cytolytic properties. Unconventional routes of complement activation include the deployment of proteolytic enzymes of the coagulation and fibrinolytic systems that can efficiently cleave both C3 and C5 into their bioactive fragments 130 . These non-canonical routes of activation, in conjunction with the intracellular complement circuitry 38, 131 , define a broader pathophysiological base of triggering cues that can initiate homeostatic or disease-tailored complement responses. 
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Phagocytic cell viable therapeutic modality and has shown promising results, particularly in the treatment of certain haemato logical malignancies, such as B cell lymphomas, multiple myeloma and chronic lymphocytic leukaemia 12, [24] [25] [26] [27] . How mAbs harness the complement system. The clini cal benefit of mAbbased immunotherapies is attributed partially to their ability to evoke complement dependent cytotoxicity (CDC) that culminates in tumour cell elimination 12, 18 . Indeed, complement has long been con sidered a potent cytolytic 'payload' for tumourspecific antibodies, and seminal studies in the early 1970s laid the groundwork for what would later become a preva lent concept in the field 28, 29 . Notably, various cancer immuno therapeutic protocols used today in the clinic rely on the twopronged capacity of mAbs to halt onco genic signalling and tumour cell growth and to simulta neously fix complement on the surface of the targeted tumour cells, thereby eliciting CDC 18, 24, 25 . Despite modest attempts to harness the cytol ytic capacity of complement in mAbbased cancer immuno therapy over the years, full realization of its tumoricidal potential came only with the US Food and Drug Administration (FDA) approval of ritux imab, a chimeric antiCD20 mAb developed for the treatment of B cell lymphomas 12, 24 . A wide array of in vitro studies using cancer cell lines, primary tumour cells, mouse tumour models and blood profiling of patients with chronic lymphocytic leukaemia after mAb infusion have provided evidence for the auxiliary, tumourdestructive role of complement in the context of antiCD20 immuno therapy 12 . mAbs targeting sur face antigens such as CD20, CD38 and CD52 that are highly expressed on B cell or T cellderived tumours are among the most wellstudied tumour specific mAbs in terms of their ability to elicit CDC 24, 27, 30 . The binding of mAbs to tumour antigens triggers the concerted activation of multiple effector pathways that operate in parallel to elicit cytolytic responses. These include CDC elicited via the classical pathway of complement activation and assembly of the membrane attack complex (MAC) 
. Concomitant recognition of the Fc portion of tumourspecific mAbs by Fcγ receptors (FcγRs) on macrophages allows for synergistic clearance of tumour cells via complement CR3 and FcγRdependent uptake (FIG. 1) . Notably, the release of complementderived inflammatory mediators, such as C5a
, further potentiates the cytolytic activity of mAbs by promoting the recruitment of phagocytic cells and skewing the rel ative expression of activating and inhibitory FcγRs on neutrophils and macrophages 31 . It should be noted, however, that a wide array of tumour cells, especially in solid tumours, have evolved diverse mechanisms by which they can limit CDC on their surfaces. Overexpression of membranebound com plement regulatory proteins (that is, CD55 (also known as complement decayaccelerating factor (DAF)), CD46 (also known as membrane cofactor protein (MCP)), and CD59) or sequestering of fluidphase regulators to the Fc portion of these antibodies leads to the assembly of the active C1 complex (C1q, C1r and C1s), which acquires proteolytic activity over complement components, initiating the cascade. Complement activation leads to tumour cell opsonization by C3-derived opsonins (C3b, iC3b and C3dg) and the generation of potent pro-inflammatory mediators (C3a and C5a), which in turn recruit and activate immune cells with phagocytic properties (neutrophils and macrophages). Downstream activation of terminal complement components results in the assembly of the pore-forming membrane attack complex (MAC), or C5b-C9, on the tumour cell membrane. The anaphylatoxin C5a is known to upregulate activating Fcγ receptors (FcγRs) on phagocytic cells, priming them for enhanced phagocytosis and increasing the magnitude of the tumour cytolytic response. C3-derived fragments (C3b, iC3b and C3dg) on tumour cells bind to CR3 and/or CR4 complement receptors on phagocytes, thus augmenting the FcγR-dependent phagocytic uptake of opsonized tumour cells.
(for example, Factor H or C4binding protein (C4BP, also known as C4BPA)) (TABLE 1) by tumour cells has been shown to prevent CDC by limiting C3 opsonization to lev els well below the threshold required for terminal pathway activation and MAC assembly [32] [33] [34] . In this regard, several strategies have been devised to overcome this impediment in mAbbased immunotherapy (discussed below).
Beyond cytotoxicity. Growing evidence indicates that complement, in addition to providing an adjunctive mechanism for mAbmediated tumour cytolysis, medi ates a plethora of immunomodulatory functions that are pertinent to tumour immunosurveillance and anti tumour immunity 35, 36 . Fundamental processes such as tumour antigen processing and presentation by anti genpresenting cells (APCs), as well as B cell activation and T helper and effector T cell survival and differentia tion, appear to be influenced by the intricate crosstalk of complement effector proteins with key cellular pathways that drive B cell and T cell responses 37, 38 . Dendritic cells (DCs), for instance, express a wide array of complement proteins and receptors 39 . In this regard, C3 deficiency has been associated with a reduced antigen presenting capac ity of APCs (lower expression of MHC class II molecules and impaired costimulation via CD80 and CD86), with important implications for autoimmune conditions and antitumour immunity 40 . Notably, the absence of C3aR or C5aR1 stimulation at the APC-T cell interface has been shown to negatively affect the survival of CD4 + T cells 41 . Moreover, genetic or pharmaco logical ablation of C3aR or C5aR1 signalling has also been linked to the induction of an immunosuppressive pheno type in CD4 + T cells in a manner that could diminish the magnitude of anti tumour effector T cell responses 42 . Further insight into the fundamental role of com plement in immune cell homeostasis has been provided by studies describing an intracellular complement cir cuitry in CD4 + T cells that modulates cell differentiation through its crosstalk with the NOD, LRR and pyrin domaincontaining 3 (NLRP3) inflammasome and the generation of reactive oxygen species (ROS) 38, 43 . Taken together, these studies support the presence of a consti tutively active complement circuitry within lymphocytes that has a role in the maintenance of the T cell pool in the periphery and may also potentiate effector T cell responses in the context of tumour immunotherapy.
Complement and cancer vaccines. Cancer vaccines represent another promising modality in cancer immuno therapy, and several studies have indicated that complement activation may contribute to vaccine efficacy through enhanced antigen uptake and co stimulatory signalling 44 . Indeed, C5a has been shown to potentiate antigen processing and presentation by human DCs 45, 46 . In this context, a C5aderived C5aR1 agonist fused to a peptidebased cancer vaccine has been tested in a preclinical model of melanoma, with encouraging results 47 . These studies point to a different therapeutic perspective whereby harnessing complement activation and triggering C5aR1dependent signalling on tumour antigenloaded DCs may help patients elicit potent anti tumour immune responses. From a different standpoint, the function of the opsonin C3dg as a molecular adjuvant that lowers the activation threshold of B cells and the role of C3derived fragments in promoting antigen retention by follicular DCs and boosting memory responses have long been appreciated as mechanisms bridging innate and adaptive immune responses 48 . However, this fun damental facet of complement biology has not been rigorously investigated in the context of cancer immuno therapy. These key immunoregulatory activities of com plement may have important implications for tumour immunotherapy and may be worth exploring during the design of antitumour vaccines.
Complement and radiotherapy.
Alongside surgical resection and chemotherapy, radiotherapy is also rec ognized as a clinical mainstay of cancer treatment, espe cially in the context of very aggressive tumours with poor prognosis 49 . Recent evidence supports a causative asso ciation between radiationinduced tumour cell damage, the tumourderived proinflammatory milieu and the potentiation of antitumour immunity 50, 51 . Interestingly, radiotherapyinduced cell death was recently shown to induce transient complement activation within solid tumours, with both tumour cells and infiltrating immune cells serving as sources of complement protein produc tion 52 . More importantly, radiotherapy was found to upregulate the release of C3a and C5a within the tumour microenvironment, inducing potent DC responses and subsequently leading to pronounced infiltration of CD8 + effector T cells into the irradiated tumours 52 . Notably, an
Box 2 | Complement: numerous proteins, plenty of functions
Soluble complement proteins are primarily produced in the liver (the exceptions being C1q and Factor D, which are secreted mainly by macrophages and adipocytes, respectively) 55 . Whereas the major 'pool' of complement is located in the blood, a variety of cell types, including fibroblasts, adipocytes and endothelial and immune cells, secrete complement proteins. A boost in complement production is often observed during inflammatory and pathologic conditions, so that virtually any tissue can be surrounded by complement activation products 13 . Such a notion of local complement is key to perceiving how imbalanced complement activation affects pathology in distinct tissues, from the skin to the kidneys, from the lung to the brain, and influences the fate of an assortment of tumour cells 3, 17, 126 . Essentially, the presence of a trigger or improper regulation results in the production of activation fragments (BOX 1) that can bind to their respective receptors on cell surfaces and elicit biological responses. Upon complement activation, C3 fragments (that is, C3b, iC3b and C3dg) that are associated with antigens bind to the complement receptors CR1 (CD35), CR3 (CD11b and CD18), CR4 (CD11c and CD18) and/or CRIg, inducing phagocytosis and modulating the function of antigen-presenting cells 13 . In turn, triggering of CR2 by iC3b and C3dg is associated with the activation of B cells 35 . Furthermore, signalling through the G protein-coupled anaphylatoxin receptors C3aR, in the case of C3a, or C5aR1 (also known as CD88), in the case of C5a and desarginated C5a (C5a-desArg), regulates cell activation, degranulation, proliferation and cytokine responses, which are essential for initiating and maintaining inflammatory responses 36 . In addition, adaptive immune responses are modulated when membrane cofactor protein (MCP, also known as CD46) is triggered on T cells 132 . Such an array of interactions between complement proteins and cell-surface receptors not only guarantees immune surveillance but also determines the outcome of immune responses, metabolic pathways and developmental processes. Proper control of the activation signals described above is required to prevent excessive activation that can lead to tissue damage and is achieved by an assortment of complement regulators (TABLE 1) that restrain certain steps of the complement cascade 133 . apparent discordance between these findings and those of a recent report showing that C3 inhibition potentiates antitumour immunity after fractionated radiotherapy 53 could be attributed to the different radiotherapeutic reg imens applied in each case and to the variable extent of tumourassociated inflammation elicited by these mod els. While these findings await corroboration in different tumour models, they provide fertile ground for consid ering complement activation as a beneficial component of radiotherapeutic protocols in various types of cancer.
Feeding inflammation and tumorigenesis
Undeniably, in the context of immunotherapy, comple ment potentiates tumour killing via its immune adjuvant properties and induction of cytolysis
. Extensive investigation of the tumour microenvironment, however, has uncovered molecular mechanisms linking imbal anced complement activation and cancer progression. The tumour microenvironment is essentially composed of genetically abnormal cells surrounded by blood ves sels, fibroblasts, immune cells, stem cells and extracellular (FIG. 2) . It is fascinating that tumours emerge from a single cell or a small number of cells bearing mutations in tumour suppressor genes and/or onco genes. To become cancerous, however, these cells must acquire several mutations in specific genes that allow pro liferation beyond the regular rate, as well as mutations that facilitate cell migration, survival in the circulation, invasion of tissues and adaptation to new tissue environ ments. In this context, it is particularly interesting that the past decade has uncovered dysregulated complement activation in the tumour microenvironment as a key link between inflammation, the suppression of antitumour immune responses and the promotion of tumorigenesis 3 .
Production and activation of complement in the tumour microenvironment. The local production of comple ment proteins by various tissues is well recognized 55, 56 (BOX 2). Furthermore, both tumour and stromal cells produce complement proteins, and evidence for local and systemic activation of complement is often observed in cancer settings 57, 58 . In line with the notion that ini tiators of complement activation can sense DAMPs 59 , complement activation appears to occur in response to tumourassociated antigens, and increased de position of complement activation fragments is commonly detected in tumour tissues. Indeed, the presence of C1q along the tumour vasculature has been detected in a rodent model of cervical cancer, and C1q has also been shown to bind directly (independent of antibodies) to phospholipids in lung tumour cell lines 22, 60 . Evidence of classical pathway activation in cancer, such as increased plasma concentrations of the C4d fragment, has been obtained from patients with lung cancer, thyroid cancer, astrocytoma, lymphoma, leukaemia, or oropharyngeal cancer 3, 60 . Moreover, signs of a deregulated alternative pathway of complement activation have been reported in patients with acute lymphoblastic leukaemia, Burkitt lymphoma or multiple myeloma, and a deregulated lectin pathway has been found in patients with T cell leukaemia 61 . Although evidence associating specific tumour antigens with differential activation of comple ment pathways is still scant, it is tempting to speculate that modified glycoproteins and glycolipids and aber rantly expressed mucins in transformed tumour cells can all act as DAMPs that are able to activate complement. Identification of such triggers would be of great value should anticomplement therapy become a reality in the adjunct treatment of cancer.
While tumour and stromal cells are active in producing complement proteins, and the local micro environment favours complement activation, complement regulates the activation status of the local cells. In the past decade, a wealth of research has provided compelling evidence regarding the role of complement in the modulation of immune cells (discussed above and BOX 2) . In addition, in vitro data indicate that complement is linked to the dif ferentiation of myeloidderived suppressor cells (MDSCs), which are seemingly involved in immune responses to cancer 22, 62 . Given that cancer development is strongly influenced by immune responses, one may assume that complement is a linking factor determining the quality and magnitude of the local antitumour immune response.
Does complement activation by infections affect tumori genesis?
Our current understanding suggests a dual role of immunity in cancer, in which pro inflammatory signals lead to DC activation, antigen presentation and consequent activation of effector T cells, while chronic inflammation, by contrast, pro motes an immunosuppressive environment that sup ports tumour progression and metastasis 63 . Indeed, epidemiological data clearly show that tumour associated inflammation is a hallmark of cancer, with close to 20% of the cancers worldwide being driven by microbial infection with organisms such as Helicobacter pylori, human papilloma virus (HPV), hepatitis virus, Epstein-Barr virus (EBV) and HIV. Although some of these infectious agents (for example, HPV and EBV) induce cell transformation directly, others pro mote tumorigenesis via local tissue inflammation 64, 65 . Whether these infections trigger complement activa tion that fuels the inflammatory response in cancer is an interesting topic for future investigation.
Complement modulates immune responses in the tumour microenvironment. Animal models have contributed immensely to increasing our understanding of the partic ipation of complement in the promotion of tumori genesis (TABLE 2) . Whereas a pioneering study demonstrated that the activation fragment C5a (BOX 1) recruits MDSCs to the tumour microenvironment, resulting in suppressed antitumour immune responses 22 , numerous other inves tigations have corroborated the view of imbalanced com plement activation as a promoter of a pro inflammatory environment that sustains tumorigenesis. MDSCs, for instance, are increasingly recognized to suppress effector T cells through deprivation of amino acids, production of nitric oxide (NO) and ROS, upregulated expression of programmed cell death 1 ligand 1 (PDL1) and secretion of angiogenic factors 66 . C5amediated acti vation of MDSCs has been associated with the induc tion of immuno modulators such as arginase 1 (ARG1), cytotoxic T lymphocyte antigen 4 (CTLA4), IL6, IL10, lympho cyte activation gene 3 protein (LAG3) and PDL1 in a murine model of lung cancer 67 . Interestingly, gener ation of C5a in this model appears to be independent of complement activation. Consistent with this observation, in vitro studies have indicated that C5a can be generated by the cleavage of C5 by serine proteases expressed on the surface of tumour cells 68 . In addition, a model of lung cancer has provided evidence to suggest that tissue factor induced coagulation leads to C5 activation and tumour promotion, further supporting the notion of local complement activation by coagulationrelated pro teases in the tumour microenvironment 69 
. C5a has also been shown to participate in tumorigenesis by upregulating the expression of molecules that suppress local immune responses such as PDL1, transforming growth factorβ (TGFβ) and IL10 (REFS 58, 70) .
Findings from two independent groups, using models of melanoma and lung cancer, have uncovered a thera peutic potential for combined blockade of the immune checkpoint molecule PDL1 and complement 71, 72 . AntiPDL1 mAbs are currently used in the clinic for the treatment of melanoma and lung cancer. By binding to its receptor PD1 (also known as PDCD1) on activated T cells, PDL1 dampens T cell receptor (TCR)mediated production of IL2 and subsequent T cell proliferation. Therefore, instead of targeting tumour cells, these mAbs block inhibitory pathways that prevent effective anti tumour responses 73 . Of note, mAbs that target immune checkpoints are designed to induce limited complement activation, CDC and ADCC. Combined ablation of C5a and PDL1induced signalling appears to be more efficient in restraining tumour growth than antiPDL1 therapy alone 71, 72 , thus indicating that complement inhi bition increases the clinical benefit of immune check point blockade. Additionally, the long pentraxin PTX3 has been shown to act as a tumour suppressor in skin, epithelial and mesenchymal carcinogenesis 21 . Evidence suggests that PTX3 is induced during carcinogenesis by IL1 and that it regulates complementderived chemo kine production via recruitment of Factor H 21 (TABLE 1) .
Most importantly, in three independent studies, the PTX3 gene was found to be methylated and silenced in selected human tumours 74 . The immunosuppressive role of C5a in cancer settings is somewhat paradoxical, considering that it induces the maturation of DCs and the differen tiation of T helper 1 (T H 1) cells 42, 75 . Such apparent contradictions were addressed in a study comparing tumour progression in mice injected with distinct murine lymphoma cell lines that secrete either low (RMA1474 cells) or high (RMA3CF4 cells) amounts of C5a. Notably, high production of C5a was associated with more prominent tumorigenesis accompanied by decreased numbers of interferonγ (IFNγ)producing CD8 + and CD4 + cells in the spleens and lymph nodes 
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Leptomeningeal metastasis (various breast cancer cell lines) C3aR C3 is upregulated in the cerebrospinal fluid in metastatic settings. C3 expression is correlated with poor disease outcome. C3aR is activated in the choroid plexus epithelium, resulting in the disruption of the blood-cerebrospinal fluid barrier. Ablation of C3aR signalling is beneficial in attenuating leptomeningeal metastasis. Abbreviations: APC, adenomatous polyposis coli; CCL, CC-chemokine ligand; CVF, cobra venom factor; CXCL, CXC-chemokine ligand; HFD, high-fat diet; MDSCs, myeloid-derived suppressor cells; NET, neutrophil extracellular traps; NK, natural killer; PD1, programmed cell death protein 1; PDL1, programmed cell death 1 ligand 1; PTX, pentraxin; RNS, reactive nitrogen species; ROS, reactive oxygen species; siRNA, small interfering RNA; TGFβ, transforming growth factor-β; TgMISIIR-Tag, transgenic mice that express the transforming region of Simian virus 40 under the control of the Mullerian inhibiting substance type II receptor and are prone to developing ovarian tumours; TILs, tumour-infiltrating lymphocytes.
104,163
of the injected mice 76 . Consistent with these findings, in vitro polarization of CD4 + T cells in the presence of increasing amounts of C5a revealed a concentration dependent polarization of T cells towards either the T H 1 cell or regulatory T (T reg ) cell lineage; high lev els of C5a (500 ng/ml) favoured the polarization of CD4 + T cells to a T reg cell phenotype instead of a T H 1 cell pheno type 76 . These observations nicely illustrate the dual role of complement in modulating immune responses. Whereas physiological concentrations of activated complement molecules can promote anti tumour immune responses, imbalanced chronic complement activation, usually preceding pathologic conditions, is associated with tumour progression.
Supporting a role for complement in tumour promo tion, the activation fragment C3a has also been impli cated in tumorigenesis. Improved disease outcome in C3aR −/− mice has been observed in a model of mela noma; tumorigenesis was associated with increased numbers of neutrophils and a proinflammatory tumour microenvironment 77 . The deleterious role of neutro phils in cancer has been further confirmed in a model of spontaneous intestinal tumorigenesis in mice with a mutation in the adenomatous polyposis coli (Apc) gene (that is, Apc Min/+ mice). In this model, tumour growth was correlated with the accumulation of neutrophils having a protumorigenic phenotype and the formation of neutrophil extracellular traps (NETs). Mechanistically, circulating lipopolysaccharide, likely leaking from the intestine, appears to induce complement activation and upregulate the expression levels of C3aR on neutrophils. C3aRmediated signalling then triggers NET release, coagulation pathways and polarization of neutrophils towards a protumorigenic phenotype 78 .
Complement in intestinal cancers. The role of comple ment in tumorigenesis is particularly interesting in the settings of intestinal and colorectal cancer because of its strong association with inflammatory bowel disease. Indeed, complement activation in a colitisassociated can cer model induced by combined administration of azoxy methane and dextran sulfate sodium has been shown to result in the induction of the pro inflammatory cytokine IL1β, mainly by infiltrating neutrophils and consequent production of IL17, a major inducer of intestinal dis ease 79 . Supporting the correlation between imbalanced complement activation, inflammation and intestinal tumorigenesis, an elegant study using a model of diet induced intestinal tumorigenesis in genetically suscep tible Apc
Min/+ mice has demonstrated that the source of dietary fat, and not obesity itself, triggers complement activation, inflammation, expression of oncogenes and intestinal polyposis; obesity and its associated metabolic changes had previously been associated with imbalanced complement activation, inflammation and cancer 80, 81 . However, the Apc Min/+ study dissociated the direct link between obesity and cancer by showing that whereas obese mice showed increased tumorigenesis when fed a highfat diet containing fat derived from corn and coco nut oil, intestinal polyposis was not observed in obese mice who were fed a highfat diet consisting of fat from olive oil 82 . In this model, tumour development was asso ciated with increased amounts of C5a, both systemically and in the intestine. As no complement activation was observed in the mice fed the olive oilbased diet, these findings pointed to a novel concept of diet induced com plement activation and raised questions as to whether and how different sources of fat or other 'trigger' foods, such as sugar, dairy and gluten, trigger an imbalanced comple ment activation in the gastrointestinal tract that could be connected with pathological conditions. Effects of complement on tumour cell proliferation and metastasis. In addition to fuelling inflammation, C3aR and C5aR1 expressed in tumour cell lines appear to signal in an autocrine manner, triggering the phospho inositide 3kinase (PI3K)-AKT pathway involved in tumour cell proliferation 57 . Similarly, sublytic levels of C5b-C9 deposited on cancer cells induce cell cycle pro gression by activating signal transduction pathways in cancer cells 83, 84 . Furthermore, complement components C5a and C1q have been implicated in promoting angio genesis in models of ovarian cancer and melanoma 85, 86 . Interestingly, triggering of cell proliferation pathways by C3a and C5a is not necessarily deleterious and has been implicated in physiological processes such as liver and retina regeneration 87, 88 . Metastatic pathways are also triggered by imbalanced complement activation and inflammation. Various mod els of tumorigenesis, including colon cancer, pancre atic cancer, squamous cell carcinoma, lung cancer and breast cancer models, support this contention by show ing increased production of complement proteins in meta static settings, followed by modulation of immune responses and establishment of an environment that suppresses effector T cells 23, 58, 89, 90 . C3aR has been fur ther implicated in the dissemination of cancer to the nervous system by disrupting the blood-cerebrospinal fluid (CSF) barrier and permitting the access of plasma components and other mitogens to the CSF 91 . Alongside the promotion of proliferation, angio genesis and metastasis, hyperactivation of complement is associated with cancer cell motility and invasiveness. Aberrant expression of C5aR1 has been detected in squamous cell carcinoma, adenocarcinoma and transi tional cell carcinoma from various organs, and vascular invasion appears to be correlated with the expression of C5aR1 (REFS 67, 92, 93) . Cell invasiveness has been shown to occur in response to C5ainduced secretion of metallo proteinases from C5aR1expressing cancer cells and degradation of ECM 68 . Interestingly, the basic helixloop-helix transcription factor twistrelated protein 1 (TWIST1), which is involved in epithelial-mesenchymal transition (EMT), binds to the promoter region of the C3 gene. C3 expression is then correlated with increased cell invasiveness through downregulation of Ecadherin on the surface of cancer cells and promotion of EMT 94 . In addition, leukaemia cell lines as well as clonogenic blasts derived from patients with chronic myeloid leukaemia or acute myeloid leukaemia show increased cell adhesion in response to C3a and C5a fragments 95 . In a model of gastric cancer, C5a promoted the invasiveness of human gastric cancer cell lines (the adenosquamous carcinoma cell line MKN1 and the tubular adenocarcinoma cell line MKN7) via conversion of RhoAguanosine diphos phate (RhoAGDP) to RhoAguanosine triphosphate (RhoAGTP), resulting in morphological cell changes and increased expression of stress fibres and filopodia 92 . Collectively, the research described above points towards local production and increased activation of complement in the tumour microenvironment that is associated with modulation of antitumour immune responses and promotion of cancer development.
Challenges of translational research
The findings discussed above might seem controversial and unlikely to be incorporated into clinical practice, especially considering that rodent models of tumori genesis do not fully recapitulate the diversity and course of human disease. Moreover, current clinical practices that rely on personalized protocols using immuno therapy, checkpoint inhibitors and vaccines are achieving favourable outcomes without considering complement responses. These concerns notwithstanding, it is remark able how consistent the involvement of complement is in such a large variety of cancer models.
The apparent discrepancy between the 'benign' complement activation that potentiates immuno therapy and the 'harmful' complement activity that sustains inflammation and tumorigenesis is likely the consequence of a fine balance between physiological levels of and imbalanced complement activation. As mentioned above, differential concentrations of C5a in the tumour microenvironment seem to regulate the quality of immune responses and determine the fate of a tumour 76 . Furthermore, increased tumori genesis, accompanied by early onset of lung metastasis and increased frequency of T reg cells and Her2 expression in the tumour microenvironment, has been observed in C3 −/− mice transgenic for the Her2/neu oncogene neuT when compared with their C3sufficient counterparts. Of particular interest is the observation that the transplantation of neuTC3 −/− malignant cells into syngeneic immunocompetent hosts results in milder pathology than does transplantation of tumour cells from neuTC3 +/+ tumours, suggesting that com plement is a key factor in immunosurveillance mech anisms in the early stages of tumorigenesis and is also involved in the immunoediting of Her2driven auto chthonous mammary tumours 96 . Given that substantial evidence associates complement with both CDC and inflammationmediated tumorigenesis, manipulation of the complement system as a means of supporting current anticancer therapies should be further explored.
Harnessing complement to enhance mAb-based immunotherapy. Immunotherapy based on mAbs, though a mainstream therapeutic option for patients with cancer, would further benefit from improvement in mAbmediated effector functions and prevention of drug resistance. To this end, antibodies with increased propensity to form hexamers (HexaBodies) upon anti gen (CD20 or CD38) binding have been engineered 97 . . Importantly, the major mechanism responsible for the antiCD20 response in patients, that is, the individ ual contributions of CDC, ADCC and phagocytosis, remains in debate 101 . In some therapeutic antiCD20 mAbs (for example, obinutuzumab) ADCC appears to be dominant over CDC when compared with rituximab or other antibodies. Preclinical and in vitro data indicate that complement activation, and in particular C3b depo sition, inhibits rituximabinduced NK cell activation and ADCC [102] [103] [104] . Further, antiCD20 mAbs have been impli cated in the induction of ROS by monocytes with con sequent inhibition of NK cellmediated cytotoxicity 105 . In light of these findings, a better understanding of the precise mechanisms triggered by therapeutic mAbs in the context of different tumours is imperative to deter mining the optimal strategy for clinical manipulation of complement in cancer patients.
Targeting complement regulators.
In line with the idea of optimizing mAb effector functions, extensive research indicates that increased resistance to CDC results in part from the expression of complement regulators (TABLE 1) by tumour cells. Indeed, increased expression of complement regulators is often observed in cancer settings [106] [107] [108] [109] [110] [111] , possibly representing a selective adapta tion by tumours to escape from host immune responses. Notably, local inflammation has also been associated with an up regulation of the regulators CD55 and CD59 in hepatomas, again supporting a role for inflammation in tumour promotion 106 . It has been reported that although there is no direct correlation between lysis of tumour cells and expression of complement regulators, the ratio between the levels of CD20 and complement reg ulators on the membrane of mantlecell lymphoma cells is indicative of their sensitivity to CDC 112, 113 . Therefore, dual targeting of tumour antigen and complement regulators has been well investigated in in vitro models [114] [115] [116] [117] [118] [119] . Although a rational approach in theory, inhibi tion of complement regulators can be challenging because of the broad expression of regulators by normal host cells and the consequent pathology associated with the lack of proper regulation of complement on cell sur faces (TABLE 1) . Nevertheless, a novel strain of NODscid IL2rγ null (NSG)Hc 1 mice with an intact complement sys tem has been generated for use as a platform for testing mechanisms underlying CDC in vivo 120 . The parental strain, NSG, allows for engraftment of primary tumours from patients and investigation of 'personalized' therapy options but is deficient in the C5 component, making it impractical for in vivo evaluation of CDC. Collectively, these studies have taught us that the clinical efficacy of CDC in immunotherapeutic protocols largely depends on multiple factors, including tumour antigen expres sion, the overall tumour burden, the distinct expression profile of complement regulators and the surface density and tertiary conformation of tumourdeposited mAbs 12 . Issues related to the potential exhaustion of comple ment stores during the administration of high doses of therapeutic mAbs and the precise contribution of each individual effector mechanism to tumour cell killing war rant further consideration when mAbbased treatment regimens are being designed.
How is complement activated in tumours?
With the exception of mAbinduced complement activation, initiators of the complement cascade in the tumour microenvironment are still elusive. Whereas comple ment activation in response to natural IgM anti bodies against tumour antigens as well as direct cleavage of C3 and C5 by tumourderived proteases have been detected in cancer settings 121 , novel insights into the mechanisms driving complement activation by specific cancer types are essential for rationalizing therapeutic approaches aimed at manipulating the complement sys tem in cancer. A variety of complement inhibitors that target distinct stages and pathways of the complement cascade are under development. These compounds are in different phases of clinical evaluation and can be potentially employed in case imbalanced complement acti vation in the tumour environment results from classical (for example, C1 inhibitor or antiC1s antibody), alternative (for example, C3 inhibitors, miniFactor H or Factor B or Factor D inhibitors) or lectin (for example, antiMASP antibodies) pathway activation or by tar geting specific effector functions (for example, C5aR1 antagonists) 122, 123 .
Complement proteins as biomarkers for cancer.
Whatever the initiation route, evidence of excessive complement activation has been detected in a variety of clinical samples. In fact, several studies have sug gested the use of complement proteins or activation fragment as biomarkers for disease diagnosis and prognosis (TABLE 3) . By the use of proteomic techniques, increased levels of C3 fragments have been identified in the serum of patients with colorectal cancer, breast can cer, pancreatic cancer, lymphoma, prostate cancer, leu kaemia, lung cancer and oesophageal cancer (TABLE 3) . It is still questionable, however, whether complement biomarkers have clinical value and can discriminate between benign and malignant tumours or if they are reliable markers of disease prognosis. Increased levels of C3 fragments, for instance, are detected in a wide variety of clinical conditions, and biomarkers identi fied by surface enhanced laser desorption ionization timeofflight (SELDITOF) mass spectrometry often represent abundant serum proteins (C3 is found at 1-2 mg/ml in the serum). Interesting findings based on samples from patients with ovarian cancer, however, have associated the expression of intratumoural C3 with disease prognosis 124 . In addition, increased lev els of a previously uncharacterized C3 fragment have been detected in prostatic fluid from cancer patients. Of note, biochemical evaluation of this C3 cleavage fragment revealed a putative prostatespecific antigen (PSA) cleavage site. Indeed, purified PSA was able to cleave C3 and C5 in vitro, suggesting that PSA acts as an immunoregulatory protease that contributes to a protumorigenic environment through the proteolysis of complement proteins 125 . Thus, whereas complement biomarkers confirm the occurrence of increased complement activation in cancer settings, the use of such markers to guide clin ical decisions is still improbable. Further insights into tumour antigens that are able to activate complement and mAbmediated complement effector functions are highly anticipated to influence current cancer therapy practices.
Conclusion
Given the multiple factors that shape the intricate interaction between complement, tumour cells and the tumour stroma, and the dynamic nature of this relationship throughout the various stages of cancer immunosurveillance and promotion (that is, tumour seeding at the primary site, immune escape, progres sion and metastasis), therapeutic manipulation of the complement system in cancer settings has great potential. Aside from further improvements in mAb induced complement cytotoxicity, special consideration should be given to exploring approaches combining the targeting of complement and immune checkpoints. Abbreviations: C1RL, complement C1r subcomponent-like; C4BP, C4b-binding protein; C5aR1, C5a receptor (CD88); DAF, decay accelerator factor; MBL, mannose-binding lectin. 
